IF0 Stock Overview A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for InflaRx Historical stock prices Current Share Price US$2.52 52 Week High US$2.62 52 Week Low US$1.08 Beta 1.67 1 Month Change 12.30% 3 Month Change 84.35% 1 Year Change 72.60% 3 Year Change -29.57% 5 Year Change -28.00% Change since IPO -80.24%
Recent News & Updates
Forecast to breakeven in 2027 Jan 01
Inflarx N.V. Announces First Patient Dosed in Phase 2A Study for Oral C5aR Inhibitor INF904 Dec 20
InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome Nov 16
InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024 Oct 31
New major risk - Revenue and earnings growth Aug 09
InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01 See more updates
Forecast to breakeven in 2027 Jan 01
Inflarx N.V. Announces First Patient Dosed in Phase 2A Study for Oral C5aR Inhibitor INF904 Dec 20
InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome Nov 16
InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024 Oct 31
New major risk - Revenue and earnings growth Aug 09
InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards) Jun 25
InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904 Jun 06
InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024 May 01
InflaRx N.V., Annual General Meeting, Apr 25, 2024 Apr 04
No longer forecast to breakeven Mar 21
InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024 Mar 21
InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024 Mar 20
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations Feb 22
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum Nov 07
New major risk - Financial position Nov 03
New minor risk - Market cap size Nov 01
InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Sep 12
Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema) Aug 31
Forecast breakeven date moved forward to 2024 Aug 12
New major risk - Share price stability Aug 11
Forecast breakeven date moved forward to 2024 Aug 10
Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023 Jun 29
Forecast to breakeven in 2025 Apr 08
InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG Jan 07
InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients Jan 06 InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd. Dec 23
InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904 Nov 10
Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients Sep 30
InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine Sep 09
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients Jul 27
InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum Jul 07
InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19 Jun 30
No longer forecast to breakeven May 18
Forecast to breakeven in 2024 Apr 27
InflaRx N.V., Annual General Meeting, Apr 28, 2022 Apr 07
InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients Apr 01
Forecast to breakeven in 2024 Mar 30
InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab Mar 01
InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma Feb 17
InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor Jan 12
InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa Jan 06
Independent Non-Executive Director Lina Ma has left the company Sep 21
InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint Sep 10
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum Aug 12
Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab Jun 09
Inflarx Announces Positive Topline Results for Vilobelimab from the U.S. Phase Ii Anca-Associated Vasculitis Ixplore Study May 12
New 90-day high: €5.29 Feb 15
InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference Feb 13
Inflarx Provides an Update on the Ongoing Development of Vilobelimab (Ifx-1), First-In-Class Anti-C5a Antibody Jan 12
New 90-day high: €4.60 Jan 07
InflaRx N.V. Completes Enrollment in Vilobelimab (Ifx-1) European Phase Ii Study in Anca-Associated Vasculitis Jan 06 InflaRx N.V. Promotes Jordan Zwick to Chief Strategy Officer
New 90-day low - €3.04 Sep 09
New 90-day low - €3.46 Aug 25
New 90-day low - €3.98 Jul 30 Shareholder Returns IF0 DE Biotechs DE Market 7D 20.8% 2.3% 0.3% 1Y 72.6% -11.7% 8.4%
See full shareholder returns
Return vs Market: IF0 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is IF0's price volatile compared to industry and market? IF0 volatility IF0 Average Weekly Movement 25.9% Biotechs Industry Average Movement 7.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IF0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IF0's weekly volatility has increased from 16% to 26% over the past year.
About the Company InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Show more InflaRx N.V. Fundamentals Summary How do InflaRx's earnings and revenue compare to its market cap? IF0 fundamental statistics Market cap €140.42m Earnings (TTM ) -€56.88m Revenue (TTM ) €168.50k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IF0 income statement (TTM ) Revenue €168.50k Cost of Revenue €773.27k Gross Profit -€604.77k Other Expenses €56.28m Earnings -€56.88m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.97 Gross Margin -358.92% Net Profit Margin -33,758.73% Debt/Equity Ratio 0%
How did IF0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 16:20 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources InflaRx N.V. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Mayur Somaiya BMO Capital Markets Equity Research Madhu Kumar B. Riley Securities, Inc.
Show 9 more analysts 
